Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening

Hepatology

Volumn 48, Issue 3, 2008, Pages 863-870

  Yeoman, Andrew D ^a   Al Chalabi, Thawab ^a   Karani, John B ^a   Quaglia, Alberto ^a   Devlin, John ^a   Mieli Vergani, Giorgina ^a   Bomford, Adrian ^a   O'Grady, John G ^a   Harrison, Phillip M ^a   Heneghan, Michael A ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BLEEDING DISORDER; CANCER RISK; CANCER SCREENING; CHILD; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; SURVIVAL RATE; SYMPTOMATOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 51349099034     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22432     Document Type: Article

References (27)

1. Bruix J, Sherman M. Management of heparocellular carcinoma. HEPATOLOGY 2005;42:1208-1236.
2. Ryder SG. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52(Suppl. III):iIi1-iii8.
3. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
4. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. HEPATOLOGY 1993;18:998-1005.
5. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333: 958-963.
6. Dover JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lecioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
8. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999 15;85:2132-2137.
9. Chen C-J, Yang H-J, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
10. Jones D, Metcalf J, Collier J, Bassendine MF, James OF. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. HEPATOLOGY 1997;26:1138-1142.
11. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: What is a clinically significant gain? J Gen Intern Med 1994;9:702-707.
12. El Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
13. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008;48:140-147.
14. Ryder SD, Koskinas J, Rizzi PM, McFarlane IG, Portmann BC, Naoumov NV, et al. Hepatocellular carcinoma complicating autoimmune hepatitis: Role of hepatitis C virus. HEPATOLOGY 1995;22:718-722.
15. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, et al. Long term benefits in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001;34:748-755.
16. Camma. C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001;34:593-602.
17. Yang Q, McDonnell SM, Khoury M, Cono J, Parrish RG. Hemochromatosis associated mortality in the United States from 1979-1992: An analysis of multipie-cause mortality data. Ann Int Med 1998;129:946-953.
18. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyeret G. Long term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
19. Kowdley K. Iron, haemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127(Suppl 1):S79-S86.
20. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004;126:102-110.
21. Saeian K, Franco J, Komorowski RA, Adams MB. Heparocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: A case series. Liver Transpl 1999;5:46-49.
22. Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004;66:383-389.
23. McGovern DP, Jewell DP. Risks and benefits of azathioprine therapy. Gut 2005;54:1055-1059.
24. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type I autoimmune hepatitis. Gastroenterology 1996;110:848-857.
25. Al-Chalabi T, Portmann BC, McFarlane IG, Heneghan MA. AST at presentation: Influence on disease course and outcomes in autoimmune hepatitis. HEPATOLOGY 206;44:638A.
26. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver diseases. N Engl J Med 1993;328:1797-1801.
27. Lee F. Cirrhosis and hepatoma in alcoholics. Gut 1966;7:77-85.